Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients

• Patients diagnosed with FD according to the ROME Ⅳ criteria，and must with symptom of bothersome postprandial fullness;
• Patients diagnosed with Stagnation of Qi according to traditional Chinese medicine;
• At least the symptom of bothersome postprandial fullness ≥4 on the Visual Analogue Scale(VAS), and the number of recurrence day must ≥3 in one week;
• Provides voluntary informed consent after receiving adequate explanation and demonstrates thorough understanding of the nature of the study.

Exclusion Criteria:

• The patients with high placebo effect, the scores in placebo run-in stage declined much than 30 percent of the mean VAS per week compare to blank run-in stage;
• Unable to take drugs orally;
• Within 7 days of Screening, the average number of stool > 2 times/day;
• Within 7 days of Screening, with the presence of ≥ type 5 stool form per the Bristol Stool Form Scale;
• History of drug or aurantium allergy;
• Patients with positive in fecal occult blood test;
• Abnormal liver and/or kidney function: creatinine >1.5*ULN (upper limits of normal), and/or AST and/or ALT > 2.0*ULN, and/or TBil > 1.5*ULN;
• Patients with family history of prolonged QT syndrome or have history of torsional apical ventricular tachycardia; or QTc > 480 ms;
• Digestive diseases, or other diseases within 6 months before Screening that may affect the swallow, absorption, or metabolism of study drugs, and not yet fully recovered judged by the Investigator;
• Patients who positive in H. Pylori test plan to accept the H. pylori eradication therapy within the trial;
• Serious complications (heart, brain, lung, liver, kidney, or blood disease);
• Neuropsychiatric disorders;
• Use of prohibited medications;
• Pregnant or lactating women or those who are planning to conceive during the study period;
• Drug abuse within 3 months, or alcohol abuse within 6 months;
• Patients participated in other clinical trials within 30 days before taking drugs;
• Other conditions deemed ineligible for enrollment by Investigator.